Skip to content
preclinicalCognitive & Anxiety

Neuropeptide Y

Also known as: NPY, Neuropeptide Tyrosine

Neuropeptide Y is a 36-amino-acid peptide and one of the most abundant neuropeptides in the mammalian brain. It is a potent orexigenic (appetite-stimulating) signal, a key regulator of stress resilience, and a powerful vasoconstrictor. NPY acts through five receptor subtypes (Y1–Y5), with Y1 and Y5 mediating appetite, Y1 and Y2 mediating anxiolysis, and Y1 mediating vasoconstriction. Its critical role in energy homeostasis makes it a major target for obesity and anxiety research.

4 cited references·5 researched benefits

Quick Answer

Neuropeptide Y (NPY) is a 36-amino-acid peptide and one of the most abundant neuropeptides in the brain, playing critical roles in appetite regulation, stress resilience, and cardiovascular function. It is the most potent orexigenic signal known, stimulating food intake through hypothalamic Y1 and Y5 receptors. NPY also promotes stress resilience — soldiers with higher NPY levels show better performance under extreme stress. Its five receptor subtypes are active drug targets for obesity and anxiety disorders.

Key Facts

Mechanism
NPY is produced by neurons throughout the central and peripheral nervous systems, with highest concentrations in the hypothalamic arcuate nucleus (appetite), amygdala (anxiety), and sympathetic neurons (vasoconstriction). It signals through five GPCRs: Y1R (Gi-coupled, anxiolytic, orexigenic, vasoconstrictive), Y2R (presynaptic autoreceptor, modulates NPY release), Y4R (binds pancreatic polypeptide preferentially), Y5R (orexigenic, synergistic with Y1R for feeding). In appetite regulation, fasting upregulates NPY expression in arcuate nucleus neurons, which project to the paraventricular nucleus to stimulate feeding behavior. In stress, NPY release in the amygdala opposes CRH-mediated anxiety responses.
Research Status
preclinical
Half-Life
~20–30 minutes
Molecular Formula
C₁₉₀H₂₈₇N₅₅O₅₇
Primary Use
Cognitive & Anxiety
Table of Contents

Benefits

  • Stress resilience — higher NPY levels correlate with improved psychological performance under extreme stress in military studiesstrong
  • Appetite regulation research target — most potent known orexigenic peptide, central to energy homeostasis understandingstrong
  • Anxiolytic properties — NPY administration in animal models produces robust anti-anxiety effects via Y1R activationstrong
  • Neuroprotection — NPY may protect against seizures and excitotoxicity through Y2R-mediated glutamate release inhibitionmoderate
  • Cardiovascular regulation — modulates heart rate, blood pressure, and cardiac remodeling through peripheral Y1R and Y2Rmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research use onlyVariable (research protocols)N/ANPY is not administered therapeutically. Research focuses on NPY receptor-selective agonists and antagonists as drug candidates. Intranasal NPY has been explored in early clinical studies for PTSD and stress-related disorders.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hyperphagia — exogenous NPY administration causes dramatic overeating in animal modelscommon
  • Vasoconstriction — peripheral NPY potentiates norepinephrine-mediated vasoconstriction, raising blood pressurecommon
  • Obesity promotion — chronic NPY elevation promotes fat deposition, particularly visceral adiposityserious
  • Immunosuppression — high NPY levels may suppress certain immune functions through Y1R on immune cellsrare

Frequently Asked Questions

How does NPY relate to stress resilience in military personnel?
Studies at Yale University found that Special Forces soldiers had significantly higher plasma NPY levels during extreme stress (SERE school survival training) compared to non-Special Forces soldiers. Higher NPY release correlated with better cognitive performance and less dissociative symptoms under stress. NPY appears to act as a natural "stress buffer" by opposing corticotropin-releasing hormone (CRH) signaling in the amygdala. This has led to exploration of intranasal NPY as a potential PTSD preventive or treatment.
Why is NPY important for obesity research?
NPY is the most potent orexigenic (appetite-stimulating) peptide known. When injected into the hypothalamus, it produces dramatic food intake increases and, with chronic administration, obesity. NPY-expressing neurons in the arcuate nucleus are activated by fasting and suppressed by leptin. In obesity, leptin resistance leads to dysregulated NPY signaling. Y1R and Y5R antagonists have been developed as anti-obesity drugs, though none have achieved FDA approval due to the complexity of redundant appetite circuits.
Can NPY be used as a treatment for anxiety?
Intranasal NPY has been tested in early clinical studies for anxiety and PTSD, with some positive signals. However, challenges include: (1) NPY does not cross the blood-brain barrier well via systemic routes; (2) intranasal delivery achieves limited brain penetration; (3) NPY receptor subtype selectivity is needed (Y1R agonism for anxiolysis vs Y5R agonism for unwanted appetite effects). Developing selective Y1R agonists that cross the blood-brain barrier is an active area of pharmaceutical research.
What is the relationship between NPY and depression?
Reduced NPY levels in cerebrospinal fluid and plasma have been reported in patients with major depression and PTSD. NPY normally opposes stress-related CRH signaling — when NPY is low, stress pathways become overactive. Some antidepressants increase NPY expression over time, which may contribute to their therapeutic effects. However, directly restoring NPY levels therapeutically remains challenging due to delivery limitations. NPY genetic variants (Val7Pro polymorphism) are associated with altered stress susceptibility.
How does NPY interact with other appetite peptides?
NPY functions within a complex network: it is co-expressed with AgRP (agouti-related peptide) in the same arcuate nucleus neurons, both promoting feeding. These NPY/AgRP neurons are opposed by POMC/CART neurons that release appetite-suppressing alpha-MSH. Leptin inhibits NPY/AgRP neurons and activates POMC neurons. Ghrelin activates NPY/AgRP neurons. Cholecystokinin (CCK) and PYY provide meal-related satiety signals that modulate NPY activity. Understanding these interactions is essential for developing effective anti-obesity therapies.

References

  1. 1
    Neuropeptide Y and stress resilience: studies in Special Forces soldiers(2000)PubMed ↗
  2. 2
    Neuropeptide Y in the control of food intake and energy homeostasis(2007)PubMed ↗
  3. 3
    NPY, stress, and the amygdala: from bench to bedside(2009)PubMed ↗
  4. 4
    Neuropeptide Y receptor pharmacology: therapeutic implications for anxiety, obesity, and cardiovascular disease(2005)PubMed ↗

Latest Research

Last updated: 2026-02-19